Sickle Cell Disease Orphan Status Lures Pharma Interest

As interest in drugs with orphan indications picks up and the science advances, sickle cell disease is attracting the attention of big pharma, with deals inked for two promising therapeutics and a variety of approaches in the clinic with partnership potential.